As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

Hollings researchers will develop AI-driven tools to better match cancer patients to marketed therapies and clinical trials.

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

NEW YORK – Ratio Therapeutics said this week that it is out-licensing its somatostatin receptor 2 (SSTR2)-targeted radiopharmaceutical discovery capabilities to Novartis. Novartis is paying Ratio $745 ...

NEW YORK – Voyager Therapeutics on Wednesday said it is developing a tau-silencing gene therapy, VY1706, for treating Alzheimer's disease and plans to seek regulatory permission to start testing it in ...